CollPlant Biotechnologies (CLGN): PRISM MarketView’s New Emerging Index Sector Addition

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN), a pioneering company in regenerative and aesthetic medicine, continues to strengthen its position in the biotech landscape and was recently added on our PRISM MarketView Emerging Beauty and Wellness Index. Powered by its proprietary recombinant human collagen (rhCollagen) platform, CollPlant is developing breakthrough technologies ranging from 3D-bioprinted tissues and organs to next-generation regenerative dermal fillers and advanced bioinks.

As of December 3, 2025, CLGN shares are trading at $2.06, marking a 3.51% decline from the previous session. The stock has shown significant volatility over the past year, moving within a 52-week range of $1.31 to $4.98. Despite the fluctuations, the company remains focused on strategic expansion, including broader rhCollagen distribution across the U.S. and Canada.

Looking ahead, CollPlant will host its Annual and Extraordinary General Meeting on December 31, 2025. Investors can expect discussions on critical proposals such as board re-elections—an event that underscores the company’s emphasis on governance, transparency, and long-term strategy.

With a market cap of approximately $26.2 million, CollPlant continues to draw interest for its innovative approach to regenerative medicine. Notably, analysts have set a 12-month price target of $11.56, reflecting confidence in the company’s growth potential and technological leadership.

CollPlant’s ongoing advancements and strategic initiatives position it as a compelling company to watch within the biotech sector.

For more information on CollPlant Biotechnologies Ltd. please visit www.collplant.com.